Huadong Medicine announced that its wholly-owned UK subsidiary Sinclair has obtained EU MDR CE certification for an injectable carboxymethyl chitosan solution, KIO015, granting it market access in the European Union. The product is the world's first and currently the only innovative non-animal-derived chitosan injectable for aesthetic medicine, used for intradermal injection, superficial filling, skin texture improvement, and skin hydration. The company is advancing the product's market launch in China, with a marketing application expected to be submitted in early 2027. This matter will not have a significant impact on the company's current financial position or operating results.
Sinclair Broadcast Group IncHuadong Medicine Co LtdSubsidiary receives EU MDR CE certification for innovative aesthetic product, enabling EU market access.
